Focus:
News
-
22 March 2019
Biogen and Eisai terminate trial of Alzheimer’s drug on efficacy grounds
Biogen and Eisai have announced they are discontinuing two Phase III trials, Engage and Emerge, evaluating the safety and efficacy of aducanumab in patients with Alzheimer’s disease and mild Alzheimer’s...
-
22 March 2019
UK MHRA recalls more batches of sartan medication
The UK Medicines and Healthcare Products Regulatory Agency has recalled three more batches of Losartan tablets amid fears of contamination with NMBA.
-
22 March 2019
FDA approves Jazz Pharma’s sleep disorder drug Sunosi
The US Food and Drug Administration has approved Ireland-based Jazz Pharmaceuticals’ Sunosi drug to treat adults suffering from excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea
-
22 March 2019
Takeda and HemoShear to develop new liver disease drugs
Takeda Pharmaceutical has expanded its exclusive drug discovery alliance with biotechnology firm HemoShear Therapeutics to discover and develop additional new therapies for liver diseases.
-
21 March 2019
Celgene signs $25m AI drug discovery partnership with Exscientia
Oxford-based artificial intelligence (AI) drug discovery company Exscientia has announced it has entered into three-year partnership with Celgene for an initial upfront payment of $25m.
-
21 March 2019
EMA publishes safety warning for Pfizer’s Xeljanz in rheumatoid arthritis
The European Medicines Agency has advised patients and clinicians to not exceed the 5mg twice daily recommendation dose of Pfizer’s Xeljanz (tofacitinib) for rheumatoid arthritis.
-
21 March 2019
Inhalable oxytocin a potential treatment for postpartum haemorrhage
Inhalable oxytocin may be used in resource-limited states to manage postpartum haemorrhage, as the result of a research agreement between Janssen Pharmaceutica, a Johnson & Johnson unit, and the Monash...
-
21 March 2019
Pfizer and Vivet Therapeutics to collaborate on Wilson disease therapy
Pharmaceutical giant Pfizer has partnered with French gene therapy company Vivet Theraputics to begin a joint project researching Wilson disease.
-
21 March 2019
Merck extends research alliance with NGM Bio
Merck has expanded the research phase of its strategic alliance with NGM Biopharmaceuticals until March 2022.
-
20 March 2019
GSK announces positive data for endometrial cancer drug dostarlimab
GlaxoSmithKline (GSK) oncology subsidiary Tesaro has unveiled promising data from its Phase I/II Garnet study evaluating dostarlimab as a monotherapy for endometrial cancer.